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Kondegowda et al. reveal how prolactin
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inhibition, even in aged mice. OPG and
Denosumab, an anti-RANKL antibody
approved for osteoporosis, enhance
human b-cell replication in humanized
mice.
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Diabetes results from a reduction of pancreatic
b-cells. Stimulating replication could normalize
b-cell mass. However, adult human b-cells are recal-
citrant to proliferation. We identified osteoprote-
gerin, a bone-related decoy receptor, as a b-cell
mitogen. Osteoprotegerin was induced by and
required for lactogen-mediated rodent b-cell replica-
tion. Osteoprotegerin enhanced b-cell proliferation in
young, aged, and diabetic mice. This resulted in
increasedb-cell mass in youngmice and significantly
delayed hyperglycemia in diabeticmice. Osteoprote-
gerin stimulated replication of adult human b-cells,
without causing dedifferentiation. Mechanistically,
osteoprotegerin induced human and rodent b-cell
replication by modulating CREB and GSK3 path-
ways, through binding Receptor Activator of NF-kB
(RANK) Ligand (RANKL), a brake in b-cell prolifera-
tion. Denosumab, an FDA-approved osteoporosis
drug, and RANKL-specific antibody induced human
b-cell proliferation in vitro, and in vivo, in humanized
mice. Thus, osteoprotegerin and Denosumab pre-
vent RANKL/RANK interaction to stimulate b-cell
replication, highlighting the potential for repurposing
an osteoporosis drug to treat diabetes.
INTRODUCTION
Type 1 (T1D) and Type 2 (T2D) diabetes result from a loss of
functional pancreatic b-cell mass caused by b-cell death and
dysfunction (Padgett et al., 2013; Weir and Bonner-Weir,
2013). Patients with long-standing diabetes retain residual
b-cells despite this loss (Oram et al., 2014). Therefore, a primary
focus for the treatment of diabetes is to normalize b-cell homeo-
stasis by reducing loss, recovering function, and enhancing
regeneration of remnant b-cells. There is evidence in rodents
that b-cell replication can be induced in response to metabolicdemand, such as pregnancy, obesity, or insulin resistance (Dor
et al., 2004; Rieck and Kaestner, 2010; Sachdeva and Stoffers,
2009). This suggests that external stimuli could be used to further
induce endogenous b-cell replication. However, the adult human
b-cell has a low rate of basal proliferation and is highly refractory
to stimulation (Parnaud et al., 2008; Perl et al., 2010).
Multiple studies have demonstrated the ability of lactogenic
hormones, prolactin (PRL) and placental lactogen (PL), to
enhance rodent b-cell function, proliferation, and survival acting
through a common PRL receptor (Guthalu et al., 2010; Vasavada
et al., 2006). Transgenic (TG) mice expressing mouse PL-1
(mPL-1) in the b-cell, under the rat insulin promoter (RIP), display
hyperinsulinemia, hypoglycemia, b-cell hyperplasia due to
increased replication, with a resultant increase in b-cell mass,
and resistance to streptozotocin (STZ)-induced diabetes and
b-cell death (Fujinaka et al., 2004; Vasavada et al., 2000). Lacto-
gens protect rodent and human b-cells against cell death
inducers relevant to T1D and T2D (Fujinaka et al., 2007; Konde-
gowda et al., 2012). PRL-R signaling is also required for normal
b-cell growth and function in development, and for the adaptive
b-cell response to the metabolic demands of pregnancy (Free-
mark et al., 2002; Huang et al., 2009). Although lactogens have
therapeutic and physiological relevance, how they modulate
b-cell proliferation is not fully understood.
To determine the molecular pathways involved in b-cell repli-
cation, microarray analysis performed on islets from three
distinct models of b-cell expansion, pregnancy, obesity/insulin
resistance, and b-cell regeneration, found Osteoprotegerin
(Opg) as one of only two common genes upregulated in islets
from all three models (Rieck et al., 2009). Opg is expressed in
rodent insulinoma cells, in rodent and human islets, and impor-
tantly, in human b-cells (Rieck et al., 2009; Kutlu et al., 2009;
Schrader et al., 2007). However, whether OPG is involved in
mediating b-cell proliferation is not known.
OPG is an unusual member of the Tumor Necrosis Factor
(TNF) Receptor Superfamily (TNFRSF), in that it lacks a trans-
membrane domain and hence is a soluble decoy receptor.
Opg (Tnfrsf11b) is expressed in numerous tissues but was
initially discovered for its role in skeletal metabolism. It inhibits
osteoclast differentiation and activation, thereby enhancing
bone formation. OPG acts by modulating two specific ligands,Cell Metabolism 22, 77–85, July 7, 2015 ª2015 Elsevier Inc. 77
Receptor Activator of NF-kB (RANK; TNFRSF11A) ligand
(RANKL; TNFSF11) and TNF-related apoptosis-inducing ligand
(TRAIL). It binds to them and thus inhibits interactions with their
respective receptors, RANK and the death receptor (DR)
(Hanada et al., 2010; Kearns et al., 2008). In vitro competition
and functional studies show that the RANKL/RANK pathway is
more sensitive to interference from OPG than the TRAIL/DR
pathway (Vitovski et al., 2007). Denosumab (DMB), a humanized
monoclonal antibody that specifically recognizes human
RANKL, acts as a partial functional equivalent of OPG, as it in-
hibits only the RANKL/RANK and not the TRAIL/DR interaction.
DMB is an FDA-approved drug for osteoporosis (Miller, 2009).
Using an unbiased analysis, we found Opg expression was
induced by lactogens in rodent islets and insulinoma cells. We
hypothesized that OPG could mediate lactogen-induced b-cell
proliferation and that OPG may directly enhance replication of
rodent and human b-cells. Indeed, the current report identifies
OPG as a downstream mediator of PRL-induced proliferation
in rodent b-cells in vivo. OPG by itself enhances rodent b-cell
replication and mass in young mice and also increases b-cell
replication in conditions relevant to diabetes: aged and STZ-
treated mice. Importantly, OPG stimulates human b-cell prolifer-
ation in vitro. Mechanistically, OPG modulates two proliferative
pathways in rodent and human islets; it inhibits glycogen
synthase kinase-3 (GSK3) and stimulates cAMP response
element-binding protein (CREB). We identified the RANKL/
RANK pathway, an OPG target, as a brake for b-cell replication
in rodent and human b-cells. DMB, an osteoporosis drug, and
a RANKL specific antibody, counteracts this brake to induce hu-
man b-cell proliferation in vitro and, more importantly, in vivo in
humanized mice. Thus, a pathway originally characterized in
bone may have therapeutic potential to normalize b-cell homeo-
stasis in diabetes.
RESULTS AND DISCUSSION
OPG Is a Target of Lactogens in b-Cells and Is Required
for Lactogen-Induced Rodent b-Cell Proliferation
Lactogens are therapeutically and physiologically important for
the b-cell (Guthalu et al., 2010; Vasavada et al., 2006). To identify
novel downstream targets of lactogens in b-cells, we used PCR-
array to examine the differential expression of genes in islets from
normal and RIP-mPL1 TG mice. Opg was upregulated in TG
versus normal islets by PCR-array; this was confirmed by real-
time PCR (Figures S1A and S1B). As islets are a composite of
many cell types, we treated the rodent insulinoma cell line,
INS-1, with PRL, to determine whether acute lactogen treatment
can induce Opg in b-cells. Indeed, Opg mRNA was induced by
PRL-treatment in INS-1 cells (Figure S1C). The increase in Opg
mRNA expression with lactogens translated to an increase in
OPG protein in PRL-treated INS-1 cells and in TG islets (Fig-
ure S1D). To examine our hypothesis that OPG mediates lacto-
gen-induced b-cell proliferation in vivo, whole-body OPG
knockout (KO) and wild-type (WT) male mice were infused with
PRL or saline for 7 days. Although basal b-cell proliferation was
similar in saline-treated WT and OPG-KO mice, PRL induced a
2.5-fold increase in b-cell replication in WT but not in OPG-KO
mice, compared to saline-treated controls (Figure 1A). This indi-
cates that OPG is required for PRL-stimulated b-cell proliferation78 Cell Metabolism 22, 77–85, July 7, 2015 ª2015 Elsevier Inc.in vivo. Taken together, these results uncover OPG as a down-
stream effector of PRL-induced proliferation in rodent b-cells
in vivo, implying that like lactogens, OPG may influence physio-
logical b-cell growth and expansion. In that context, OPG is
increased in islets from pregnant mice (Rieck et al., 2009), as
well as in the circulation of pregnant women (Hong et al., 2005).
OPG Enhances Rodent b-Cell Proliferation in Young,
Aged, and STZ-Treated Mice
As Opg is increased in three models of b-cell expansion (Rieck
et al., 2009) and was required for lactogen-induced b-cell prolif-
eration (Figure 1A), we tested whether OPG can stimulate rodent
b-cell replication. C57BL/6 male mice injected daily with mouse
recombinant OPG (mOPG-Fc) at 0.01–1.0 mg/g body weight for
7 days were assessed for b-cell proliferation by co-staining for
insulin and BrdU (Figure 1B). OPG at lower doses (0.01–
0.05 mg/g) induced a 2- to 3-fold increase, and at the higher
doses (0.5–1.0 mg/g) induced a significant 5- to 6-fold increase
in b-cell replication relative to saline-treated mice (Figure 1C).
This was validated by staining for an endogenous proliferation
marker, phospho-Histone H3 (pHH3), which confirmed the in-
crease in b-cell replication observed with 1.0 mg/g of mOPG-Fc
(Figure 1D). Body weight, blood glucose, or basal rate of b-cell
death did not change in these mice (Figures S2A–S2C). Glucose
homeostasis, as measured by plasma insulin and intraperitoneal
glucose tolerance test (IPGTT), significantly improved in mice
treated with 1.0 mg/g of mOPG-Fc (Figures S2D–S2F).
To determine whether OPG-induced b-cell proliferation yields
increased b-cell mass, we treated C57BL/6 mice every alternate
day for 30 days with 1.0 mg/g of mOPG-Fc. Indeed, b-cell repli-
cation was increased at day 30 (Figure 1E), and there was a sig-
nificant 20% increase in b-cell mass (Figure 1F) in mice
receiving mOPG-Fc relative to controls. However, body weight,
blood glucose, b-cell death, IPGTT, and insulin tolerance test
(ITT) did not significantly differ between mOPG-Fc-treated
versus control micewith the longer treatment (Figures S3A–S3F).
Thus, OPG induces rodent b-cell replication in vivo in young
mice within a span of 1–4 weeks, causing a transient improve-
ment in glucose homeostasis with the shorter treatment. An in-
crease in cell proliferation markers does not necessarily equate
to an increase in cell number, depending on whether cells com-
plete the cell cycle or whether there is a concomitant increase in
cell death. However, the significant increase in b-cell mass
observedwith the prolonged treatment together with no increase
in b-cell death, indeed suggests that OPG-induced proliferation
results in an increase in b-cell number, at least in vivo.
Contrary to our findings, a recent report found that injecting
human OPG at low doses (1.0 mg/mouse) and infrequent inter-
vals in mice caused islet inflammation and b-cell death, resulting
in hypoinsulinemia and hyperglycemia (Toffoli et al., 2011). In-
jecting human OPG in rats generates antibodies against the
human peptide (Mochizuki et al., 2002). Thus, use of species-
incompatible OPG, together with the extremely low-dose and
intermittent regimen, could probably lead to the negative effects
observed in the study (Toffoli et al., 2011). In contrast, studies
using two distinct transgenic rodent models of OPG overexpres-
sion, with systemic elevation of rodent OPG at levels 5- to 200-
fold over endogenous, did not find changes in blood glucose
levels even at 1 year of age, suggesting that chronic high levels
Figure 1. OPG Is Required for PRL-Induced Rodent b-Cell Proliferation and Enhances Rodent b-Cell Replication in Young, Aged, and STZ-
Treated Mice
(A) Percentage of BrdU-positive b-cells in male OPG KO andWTmice infused with Vehicle (Veh) or PRL for 7 days. b-cell proliferation inWT-Vehmice is depicted
as 100% (n = 4–5 mice/group); *p < 0.05 versus other three groups; (see also Figure S1).
(B) Representative images of pancreatic sections stained for insulin (green) and BrdU (red) frommice injected daily for 7 days with vehicle (Veh) and 1.0 mgmOPG-
Fc/g body weight. Arrows indicate BrdU- and insulin-positive cells.
(C) Percentage of BrdU-positive b-cells in 10-week-old mice injected daily for 7 days with Veh or different doses of mOPG-Fc; (n = 5–10 mice/group, >1,000
b-cells counted/mouse; see also Figure S2).
(D) Percentage of pHH3-positive b-cells in mice treated as in (B).
(E) Percentage of BrdU-positive b-cells in mice injected every alternate day with Veh or 1.0 mg/g mOPG-Fc/g for 30 days; (n = 5 mice/group; see also Figure S3).
(F) b-cell mass in mice treated as in (E); *p = 0.05 versus Veh.
(G) Percentage of BrdU-positive b-cells in 1-year-old mice injected daily with Veh or 1.0 mg/g mOPG-Fc for 7 days (n = 6–7 mice/group).
(H) Percentage of BrdU-positive b-cells in MLDS mice injected daily with Veh or 1.0 mg/g mOPG-Fc for 16 days (n = 7–8 mice/group).
(I) Percentage of TUNEL-positive b-cells in mice treated as in (H).
(J) Diabetes incidence, defined as blood glucose > 250mg/dl, inmice treated as in (H); #p < 0.05 versus Veh by chi-square test. All values are presented asmean ±
SEM. *p < 0.05 versus Veh, except where specified otherwise.of OPG do not negatively impact glucose homeostasis (Ominsky
et al., 2009; Simonet et al., 1997).
A relevant question in the context of diabetes is whether OPG
can induce b-cell proliferation under conditions of increased
metabolic demand. We tested the effect of OPG: (1) in aged
mice, known to have insulin resistance and low b-cell replication
(Teta et al., 2005); and (2) in the multiple low dose STZ (MLDS)-
induced diabetes model, with increased b-cell death and hyper-
glycemia (Leiter, 1982). One-year-old C57BL/6mice treated with
1.0 mg/g of mOPG-Fc for 7 days showed a significant 2-fold in-
crease in b-cell proliferation compared to control mice (Fig-
ure 1G). Injection of mOPG-Fc in MLDS-treated mice caused a
significant increase in b-cell proliferation (Figure 1H), and reduc-tion in b-cell death (Figure 1I) by 16 days, compared to vehicle-
injected MLDS mice. Importantly, this resulted in a signifi-
cant delay in the incidence of diabetes (defined as blood
glucose > 250 mg/dl) (Figure 1J), in OPG-treated versus
vehicle-treated MLDS mice. These findings indicate that OPG
is beneficial to the b-cell not only in young normal mice but is effi-
cacious also under conditions of increased metabolic demand.
OPG Stimulates Rodent and Human b-Cell Proliferation
In Vitro without Causing Dedifferentiation
To examine whether OPG can directly stimulate b-cell prolifera-
tion, we treated mouse islet cells with mOPG-Fc in culture for
24 hr. OPG increasedmouse b-cell replication in vitro (Figure 2A),Cell Metabolism 22, 77–85, July 7, 2015 ª2015 Elsevier Inc. 79
Figure 2. OPG Stimulates b-Cell Proliferation and Increases Phosphorylation of CREB and GSK3 in Rodent and Human Islets In Vitro
(A) Percentage of BrdU-positive b-cells in mouse islet cell cultures treated with Vehicle (Veh) or 0.1 mg/ml of mOPG-Fc for 24 hr in the presence of BrdU (n = 3).
(B) Representative confocal images of human islet cell cultures treated with Veh or 0.1 mg/ml of hOPG-Fc and BrdU for 24 hr and stained for insulin (green), BrdU
(red), and DAPI (blue).
(C) Percentage of BrdU-positive human b-cells treated with Veh or different doses of hOPG-Fc for 24 hr; (n = 4–6 human islet preps; see also Figure S4).
(D) Percentage of Ki67-positive human b-cells as treated in (C) for 24 or 72 hr.
(E) Representative western blot analysis and quantitation of phCREB/tubulin ratio in mouse islets treated with Veh or mOPG-Fc for varying times.
(F) Analysis as in (E) of phGSK3/tubulin ratio.
(G) Representative western blot analysis and quantitation of phCREB/tubulin ratio in human islets treated with Veh or hOPG-Fc for varying times.
(H) Analysis as in (G) of phGSK3/tubulin ratio. (n = 3–6 islet preps). All values are presented as mean ± SEM. *p < 0.05 versus Veh.suggesting a direct effect of OPGon the b-cell. Amajor challenge
in this field is inducing replication of adult human b-cells. There-
fore, we tested whether human OPG-Fc (hOPG-Fc) could stimu-
late adult human b-cell proliferation. In fact, 0.05 and 0.1 mg/ml of
hOPG-Fc caused a significant 3-fold increase in human b-cell
replication in vitro by 24 hr, as assessed by BrdU-insulin co-
staining (Figures 2B and 2C). We verified this by staining for a
different proliferation marker, Ki67, which showed a similar
3-fold increase in human b-cell replication with 0.1 mg/ml of
hOPG-Fc at 24 hr and 72 hr (Figure 2D). Inducing human b-cell
proliferation in vitro can lead to dedifferentiation of b-cells (Beat-
tie et al., 1999). To determine whether OPG affected differentia-
tion of human b-cells, gene expression of hormones, a glucose
sensor, and transcription factors (Figure S4A; Table S2), and in-
sulin content (Figure S4B) weremeasured in human islets treated
with hOPG-Fc for 24 hr. There was no significant change in these80 Cell Metabolism 22, 77–85, July 7, 2015 ª2015 Elsevier Inc.parameters in OPG- versus vehicle-treated islets. To further
ensure at the cellular level that OPG does not induce dedifferen-
tiation of proliferating cells, we co-stained OPG-treated human
islet cells (Figure S4C) and mouse pancreatic sections (Fig-
ure S4E) for the proliferation marker Ki67 or BrdU and the
b-cell transcription factor NKX6.1 or PDX1. Clear co-staining of
the proliferation marker and the transcription factor was
observed in human and mouse islets (Figures S4C and S4E).
There was a significant increase in the double-positive cells in
OPG-treated versus vehicle-treated human and rodent islets
(Figures S4D and S4F).
A major limitation, and therefore a focus in diabetes research,
is to find ways to normalize human b-cell homeostasis under
conditions of stress. This study ascribes OPG, originally
described in bone, with a role in stimulating human b-cell prolif-
eration. The recalcitrance of adult human b-cells to proliferate is
Figure 3. OPG Induces Human b-Cell Prolif-
eration by Interfering with RANKL/RANK,
which Acts as a Brake in b-Cell Replication
(A) Competition assay in which human islet cell
cultures treated with either Veh (-), 0.1 mg/ml of
hOPG-Fc, or hRANKL, or the combination of
hRANKL/hOPG-Fc at a 1:1, 1:5, or 5:1 ratio, and
BrdU for 24 hr, were assessed for percentage of
BrdU-positive b-cells (Veh as 100%; n = 3–8
human islet preps); *p < 0.05 versus the four
remaining groups.
(B) Representative images of islet cell cultures
from Rank-lox mice transduced with Ad-LacZ or
Ad-Cre for 72 hr and stained for insulin (red), Ki67
(green), and DAPI (blue).
(C) Percentage of Ki67-positive b-cells in Ad-LacZ
(as 100%) and Ad-Cre transduced Rank-lox islet
cells (n = 3); *p < 0.05 versus Ad-LacZ. All values
are presented as mean ± SEM.well known (Parnaud et al., 2008; Perl et al., 2010). The average
age of the human islet donors for these studies was 46 ±
2.5 years, ranging from 18 to 62 years (Table S1), indicating
that OPG can stimulate replication of adult human b-cells. An
important question in this field is whether a 2- to 3-fold increase
in the very low basal level of human b-cell proliferation is suffi-
cient to cause a clinically meaningful difference in b-cell mass.
In rodents, a comparable increase in b-cell proliferation leads
to measurable increase in b-cell mass within a few weeks (Fig-
ure 1F; Williams et al., 2011). Since OPG-induced b-cell prolifer-
ation did not cause b-cell dedifferentiation in human islets, this
suggests that a consistent but low increase in human b-cell repli-
cation may be adequate to restore sufficient functional b-cell
mass over time.
OPG Increases Phosphorylation of CREB and GSK3 in
Rodent and Human Islets
To investigate the signaling pathways through which OPG could
mediate its proliferative effects in b-cells, we treated mouse and
human islets for varying times with species-compatible OPG-Fc
and assessed by western blot analysis for modulation of
signaling pathways known to be important in b-cell proliferation
(Kulkarni et al., 2012). OPG did not affect the phosphorylation of
extracellular-signal-regulated kinases 1/2 (ERK1/2; data not
shown) but significantly enhanced phosphorylation of CREB
andGSK3 in rodent islets (Figures 2E and 2F) and in human islets
(Figures 2G and 2H). Thus, OPG induced phosphorylation of two
pathways previously shown to be important regulators of b-cell
proliferation (Hussain et al., 2006; Kulkarni et al., 2012; Liu
et al., 2009). OPG inactivated the negative-regulator GSK3 and
activated the positive-regulator CREB in both rodent and human
islets.
OPG Induces Human b-Cell Proliferation by Interfering
with RANKL/RANK, a Brake for b-Cell Replication
We hypothesized that OPG induces b-cell replication through in-
hibiting the RANKL/RANK pathway, as it is more sensitive to in-
hibition by OPG than TRAIL/DR interactions (Vitovski et al.,
2007). The receptor for this pathway, RANK, and RANKL are ex-
pressed in human islets and human b-cells (Kutlu et al., 2009;Schrader et al., 2007). We used a competition assay to assess
the role of the RANKL/RANK pathway in OPG-induced human
b-cell proliferation. Human islet cell cultures were treated with
vehicle, 0.1 mg/ml of either hOPG-Fc or human RANKL
(hRANKL), or the combination of the two peptides at a 1:1 ratio
or an excess of each peptide at a 5:1 ratio, and b-cell replication
quantified after 24 hr. As expected, hOPG-Fc alone stimulated
human b-cell proliferation, whereas hRANKL alone did not
further decrease the low rate of basal human b-cell replication
(Figure 3A). The combination of hRANKL/hOPG-Fc at a 1:1 or
5:1 ratio completely blockedOPG-induced human b-cell replica-
tion (Figure 3A); however, increasing OPG concentration 5-fold
reversed the inhibition by RANKL, implying that OPG induces hu-
man b-cell proliferation by interrupting RANKL/RANK interac-
tion. If RANKL/RANK is indeed a brake for b-cell proliferation,
we hypothesized that deletion of RANKwill induce b-cell replica-
tion. To examine this, we genetically deleted Rank by trans-
ducing islet cells from Rank-lox mice with adenovirus (Ad)-Cre
recombinase, or Ad-LacZ as control, and measured b-cell prolif-
eration. Cre-transduced islets displayed a significant 2-fold in-
crease in b-cell replication compared to LacZ-transduced islets
(Figures 3B and 3C), indicating that deletion of Rank induces
b-cell proliferation. Thus, using two complementary approaches,
competition assay and genetic deletion, we demonstrate that the
RANKL/RANK pathway is a brake for b-cell proliferation in rodent
and human islets, which can be overcome by OPG.
FDA-Approved Osteoporosis Drug, Denosumab,
Increases Human b-Cell Proliferation In Vitro and In Vivo
If RANKL/RANK is a negative modulator of human b-cell replica-
tion, then Denosumab (DMB), an osteoporosis drug that specif-
ically inhibits hRANKL (Miller, 2009), should stimulate human
b-cell replication. Indeed, DMB significantly increased human
b-cell proliferation in vitro as assessed by two different methods:
BrdU-insulin (Figure 4A) and Ki67-insulin (Figures 4B and 4C) co-
staining at 24 hr and 72 hr. This further validates the RANKL/
RANK pathway as a brake for human b-cell proliferation.
An essential aspect in the treatment of diabetes is the ability to
stimulate adult human b-cell replication in vivo. To test whether
DMB can achieve this, we transplanted human islets under theCell Metabolism 22, 77–85, July 7, 2015 ª2015 Elsevier Inc. 81
Figure 4. DMB Increases Human b-Cell Proliferation In Vitro and In Vivo
(A) Percentage of BrdU-positive b-cells in human islet cell cultures treated with Vehicle (-) or different concentrations of DMB and BrdU for 24 hr.
(B) Human islet cell cultures treated with Veh or 0.1 mg/ml of DMB for 24 hr and stained for insulin (red), Ki67 (green), and DAPI (blue).
(C) Percentage of Ki67-positive human b-cells treated with Veh (-) (as 100%) or 0.1 mg/ml of DMB for 24 or 72 hr; (n = 3–5 human islet preps).
(D) Experimental design of human islets transplanted under the kidney capsule of male euglycemic NOD/SCID mice.
(E) Representative images of human islet grafts in the kidney capsule of Vehicle (Veh)- or DMB- (1 mg/g) treated mice stained for insulin (green) and BrdU (red).
Arrow represents BrdU-positive b-cell.
(F) Percentage of BrdU-positive b-cells in human islet grafts of Veh and DMB-treated mice (n = 5 human islet preps; 1,427 ± 121 b-cells counted/prep). All values
are presented as mean ± SEM. *p < 0.05 versus Veh.kidney capsule of euglycemic immunodeficient non-obese dia-
betic/severe combined immunodeficient (NOD/SCID) mice.
One week post-transplant, the mice were given a single injection
of either vehicle or 1 mg/g of DMB. The DMB regimen was based
on the dose used in humans and in humanized RANKL mice to
treat osteoporosis (Kostenuik et al., 2009; Miller, 2009). The kid-
ney bearing the human islet graft was harvested a week later
(Figure 4D), to assess human b-cell death and proliferation.
b-cell death was negligible in the islet grafts of vehicle- or
DMB-treated mice (data not shown). Human b-cell replication
measured by BrdU-insulin co-staining (Figure 4E) was absent
or extremely low in the islet graft of vehicle-treated mice. In
contrast, DMB significantly increased human b-cell proliferation
in the human islet grafts in vivo (Figure 4F) in a humanized mouse
model, validating our observations that the RANKL/RANK
pathway is a brake for human b-cell replication. It is possible
that injecting DMB earlier at the time of islet transplant, or pro-
longing the treatment beyond 7 days, may further enhance
b-cell proliferation in the islet graft. Future studies will determine
whether either hOPG-Fc or DMB will have beneficial effects on82 Cell Metabolism 22, 77–85, July 7, 2015 ª2015 Elsevier Inc.human islets transplanted into diabetic mice to normalize
hyperglycemia.
A recent study in postmenopausal women analyzing glucose
homeostasis and diabetes incidence in post hoc analyses of ran-
domized, placebo-controlled trials in women taking DMB versus
placebo for 3 years did not find any significant changes in these
parameters (Schwartz et al., 2013). However, whether DMB will
have any effect on glucose homeostasis in patients with diabetes
has not been examined. In a prospective population-based
study, high serum concentration of soluble RANKL was a signif-
icant and independent risk predictor of T2D, whereas increase in
circulating OPG which occurred later was unrelated to T2D risk
(Kiechl et al., 2013).
These findings imply that inhibiting the RANKL/RANK pathway
can have therapeutic potential for the b-cell. This raises an
important issue regarding the specificity of targeting this
pathway in the b-cell. The RANKL/RANK pathway has roles in
many tissues, including bone (Hanada et al., 2010; Kearns
et al., 2008). Therefore, systemic inhibition of this pathway
through OPG or DMB could likely enhance bone formation.
There is evidence that patients with T1D and T2D, including chil-
dren, have an increase in the incidence of bone fractures due to
decreased bone strength (Isidro and Ruano, 2010; Saito et al.,
2014). In that case, the off-target effect of these molecules on
bone may actually be beneficial. A recent report found that treat-
ment with OPG, or genetic disruption of the RANKL/RANK
pathway, led to improved insulin sensitivity in the insulin-resis-
tant ob/ob mouse, indicating an advantageous off-target effect
of OPG in the context of diabetes (Kiechl et al., 2013). Impor-
tantly, long-term increase in systemic OPG levels in transgenic
rodents did not affect immune or mammary gland function,
two other known targets of RANKL action (Kearns et al., 2008).
Of clinical relevance, DMB is currently an osteoporosis drug, a
testament to its relative safety, despite its multi-organ actions.
The current study uncovers a link in gene expression and func-
tion between Opg and lactogen signaling in the b-cell, implying
that OPG, like lactogens, is important in b-cell physiology. It
identifies RANKL/RANK as a brake in b-cell replication. OPG
and DMB counteract this brake to stimulate human b-cell prolif-
eration, indicating that they could regulate b-cell homeostasis
under stress. The proliferative effect of DMB on human b-cells
in vivo suggests that there is potential for repurposing this oste-
oporosis drug for diabetes.
EXPERIMENTAL PROCEDURES
Peptides
Recombinant (r) hOPG-Fc and rmOPG-Fc were procured from R&D Systems;
rhRANKL from Enzo Life Sciences; Denosumab (Prolia) from Amgen; and
ovine PRL from Sigma. The vehicle to reconstitute these peptides was PBS
with 0.1% BSA, saline, or DMB vehicle (Prolia).
Treatment in Mice
C57BL/6 8- to 10-week-old or 1-year-old male mice (Jackson Laboratories)
were injected subcutaneously (sc) with saline or different doses (0.01–
1.0 mg/g body weight) of mOPG-Fc, either daily for 7 days or every alternate
day for 30 days. In theMLDSmodel, 10-week-old C57BL/6 male mice injected
daily for 5 days with 50 mg/kg of STZ were administered vehicle or mOPG-Fc
(1.0 mg/g body weight) daily for 16 days, with blood glucose measured every
alternate day. 12- to 14-week-old male OPG-KO (Jackson Labs) andWT litter-
mates were infused with either saline or oPRL (0.175 mg/hr) for 7 days using
Alzet micro-osmotic pumps (DURECT Corporation) implanted sc between
scapulae. Pancreata were harvested 6 hr after an intraperitoneal BrdU
(50 mg/g, Sigma) injection. All animal studies were performed with the approval
of, and in accordance with, guidelines established by the University of
Pittsburgh, and the Icahn School of Medicine at Mount Sinai, and principles
of laboratory animal care were followed.
Glucose Homeostasis
Body weight and blood glucose were measured twice a week; IPGTT was
done on days 5 and 25; and ITT was done on day 21. Blood glucose was
measured on tail snips using a portable glucometer (Alphatrak). IPGTT
was performed in mice fasted for 16–18 hr injected with 2 g glucose/kg
body weight. ITT was performed in mice injected sc with 1.5 U/kg of human
insulin, humulin (Lilly). Plasma insulin was measured on blood drawn at the
end of the study, using an insulin ELISA kit (Mercodia; Williams et al., 2011).
INS-1 Cells, Islets, Ad-transduction
Rat insulinoma cell line INS-1 was a generous gift from Dr. Doris Stoffers (Uni-
versity of Pennsylvania School of Medicine) and cultured as previously indi-
cated (Fujinaka et al., 2007). Human islets were obtained from the Integrated
Islet Distribution Program (IIDP; Table S1). Human islets were harvested
from deceased donors without any identifying information with informed con-
sent and IRB approval at the NIH-approved islet-isolating centers. Mouseislets were isolated by collagenase digestion and histopaque gradient separa-
tion. Islets were kept in complete media (RPMI with 5.5 mM glucose, 10% fetal
calf serum, and 1% penicillin-streptomycin) for at least 24 hr, before they were
hand-picked under the microscope for treatment and analysis. Mouse islets
were isolated from 5- to 6-month-old RIP-mPL1 TG and normal littermates
for gene expression, 8- to 20-week-old C57BL/6 or CD1 mice for signaling
pathway analysis, 8- to 10-week-old C57BL/6 male mice, and 8- to 12-
week-old Rank-lox mice for b-cell proliferation analysis. Recombinant Ad
were generated and purified as described earlier. Trypsinized Rank-lox islet
cell cultures were transduced with Ad-LacZ or Ad-Cre recombinase (Gene
Transfer Vector Core) at a multiplicity of infection of 100 in a volume of 50 ml
of complete media for 2 hr, after which 1 ml of media was added. After
72 hr, cells were fixed in 2% paraformaldehyde for 30 min (Kondegowda
et al., 2012; Williams et al., 2011).
b-Cell Histomorphometry and Immunostaining
Pancreata were weighed, fixed in Bouin’s (Sigma), and paraffin embedded.
Histomorphometry for b-cell mass was performed in a blinded way on 5–7 in-
sulin-stained pancreatic sections per animal separated by 50 mm each, using
the Optimas software package. b-cell mass was quantified per animal as the
ratio of the insulin-positive to total pancreatic area, multiplied by the pancreas
weight and averaged for all the sections/mouse. b-cell proliferation was quan-
tified as percentage of BrdU-insulin or pHH3-insulin to total insulin-positive
cells. Pancreatic sections were stained with antibodies against insulin (Dako)
and BrdU (1:200 dilution, Abcam) or pHH3 (1:500, Millipore), using an immuno-
fluorescence secondary antibody (Williams et al., 2011). Mouse pancreatic
sections were co-stained for BrdU and PDX1 (1:300, EMD Millipore), and
DAPI. b-cell death was quantified as a percentage of TUNEL-insulin to total in-
sulin-positive cells on pancreatic sections stained with antibodies against in-
sulin and TUNEL (Promega) (Williams et al., 2011). In human islet transplant
studies, mice were injected with BrdU on day 14, and 6 hr later the kidney
with the islet graft was harvested, fixed in Bouins, and b-cell proliferation
was analyzed on at least 3–4 BrdU-insulin co-stained sections/islet graft and
b-cell death on TUNEL-insulin co-stained sections.
For in vitro studies, mouse and human islets were trypsinized and cultured
on glass coverslips in complete media for 24 hr. Subsequently the cells were
cultured in serum-free medium containing either vehicle or species-compat-
ible OPG-Fc, or DMB at specific concentrations, with BrdU (10 mg/ml) added
in the last 24 hr of treatment, after which they were fixed in 2% paraformalde-
hyde for 30 min. b-cell proliferation was quantified using either BrdU or Ki-67
co-staining with insulin (Vasavada et al., 2007). Human islet cells were co-
stained with Ki67 (1:300, Thermo Scientific) and NKX6.1 (1:300, DSHB at the
University of Iowa) and DAPI.
mRNA and Protein Analysis
Gene expression in RIP-mPL1 TG and normal islets incubated in serum-free
medium for 24 hr, in INS-1 cells treated with 0.2 mg/ml of PRL or vehicle in
serum-free medium for 24 hr, and human islets treated with vehicle or
0.1 mg/ml of hOPG-Fc in serum-free medium for 24 hr was analyzed by
PCR-array (apoptosis for mouse, SA Biosciences), or by real-time PCR (ABI
7300; Life Technologies), after mRNA isolation and cDNA synthesis using spe-
cific primers indicated in Table S2. Western blot analysis of islet extracts (20–
30 mg) from RIP-mPL1 TG and normal islets, and INS1 cells treated with PRL or
vehicle in serum-free medium for 24 hr, was done using antibodies to OPG
(Santa Cruz Biotech), and tubulin (EMD Millipore-Calbiochem). For analysis
of cell signaling, protein extracts (15–20 mg) from mouse or human islets
pre-treated overnight in serum-free medium and subsequently treated with
species-compatible OPG-Fc (0.2 mg/ml) for varying times were analyzed for
phospho-CREB, phospho-GSK3a/b, phospho-ERK1/2 (Cell Signaling), and
tubulin by western blot analysis. Quantitative densitometry of digitalized blots
was performed using the Image J program (National Institute of Health) (Wil-
liams et al., 2011). Insulin content in human islets treated with vehicle or
0.1 mg/ml of hOPG-Fc in serum-free medium for 24 hr was analyzed on
acid-ethanol extracts by RIA for human insulin (Linco Research).
Human Islet Transplants
Two 8- to 12-week-old male euglycemic NOD/SCID mice (Jackson Labs)
were transplanted under the kidney capsule with 1,000 islet equivalentsCell Metabolism 22, 77–85, July 7, 2015 ª2015 Elsevier Inc. 83
(IEQ; 1 IEQ = 125 mmdiameter) of each human islet prep (Rao et al., 2005). Mice
were injected sc with vehicle or DMB (1 mg/g body weight) at day 7 post-trans-
plant. On day 14, the kidney with the islet graft was harvested for b-cell prolif-
eration and b-cell death analysis. Ages of donors of human islets range from 46
to 61 years (Table S1).
Statistical Analysis
Data are expressed as means ± SEM. Statistical significance was considered
at p% 0.05, determined by unpaired two-tailed Student’s t test for comparison
between two groups; by one-way ANOVA with Tukey’s post hoc HSD (http://
statistica.mooo.com) for comparison between more than two groups, and by
chi-square test for diabetes incidence.
SUPPLEMENTAL INFORMATION
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